As of September 30, 2023, the Company’s cash, restricted cash, and investments were $46 million, compared to $34.1 million reported on December 31, 2022. In the first quarter of 2023, the Company raised a gross amount of $27.5 million through a registered direct offering. During the third quarter of 2023, the Company used $5.4 million to fund its activities. Existing cash and cash equivalents are expected to provide sufficient funds for the Company’s current operating plan through profitability. The Company’s issued and outstanding shares of NIS 0.07 par value as of December 31, 2022, June 30, 2023, and September 30, 2023, were 7,240,020, 9,216,520 and 9,219,261, respectively.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MDWD:
- MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
- MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update
- MediWound to Report Third Quarter 2023 Financial Results
- MediWound receives positive CHMP opinion on NexoBrid in pediatric patients
- MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients
